keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant in lung cancer

keyword
https://www.readbyqxmd.com/read/29130233/-clinical-features-and-prognosis-analysis-of-21-gastric-cancer-patients-with-pathological-complete-response-after-neoadjuvant-chemotherapy
#1
Liangqun Peng, Wei Yang, Zhandong Zhang, Hongxing Liu, Yawei Hua
OBJECTIVE: To evaluate the clinical features and prognosis of gastric cancer patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). METHODS: Clinical data of 159 gastric cancer patients who received NAC followed by surgical resection between January 2012 and December 2014 at the Affiliated Tumor Hospital of Zhengzhou University were collected and clinical features of those with pCR were analyzed retrospectively. Kaplan-Meier method was used to estimate 3-year overall survival (OS) rate and recurrence-free survival (RFS) rate...
October 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29124429/what-factors-determine-the-survival-of-patients-with-an-acute-exacerbation-of-interstitial-lung-disease-after-lung-cancer-resection
#2
Masahiro Miyajima, Atsushi Watanabe, Toshihiko Sato, Satoshi Teramukai, Masahito Ebina, Kazuma Kishi, Yukihiko Sugiyama, Haruhiko Kondo, Satoru Kobayashi, Yutaka Takahashi, Hiroyuki Ito, Ryoji Yamamoto, Shigeki Sawada, Hideki Fujimori, Kazunori Okabe, Jun Arikura, Yasushi Shintani, Hiroshige Nakamura, Shinichi Toyooka, Tohru Hasumi, Takehiro Watanabe, Yoshinobu Hata, Hisashi Iwata, Minoru Aoki, Kazuhito Funai, Shuhei Inoue, Osamu Kawashima, Tomohiko Iida, Hiroshi Date
PURPOSES: Acute exacerbation of interstitial pneumonia (AEIP) is a leading cause of death after lung cancer resection in patients with interstitial lung disease. METHODS: We retrospectively analyzed 1763 patients with non-small cell lung cancer with a clinical diagnosis of interstitial lung disease (ILD) who underwent lung cancer resection between 2000 and 2009 at 61 hospitals in Japan. AEIP occurred in 164 of 1763 (9.3%) patients with a mortality rate of 43.9% (72/164)...
November 9, 2017: Surgery Today
https://www.readbyqxmd.com/read/29114590/oncological-outcomes-from-trimodality-therapy-receiving-definitive-doses-of-neoadjuvant-chemoradiation-%C3%A2-60%C3%A2-gy-and-factors-influencing-consideration-for-surgery-in-stage-iii-non-small-cell-lung-cancer
#3
Melissa A L Vyfhuis, Neha Bhooshan, Whitney M Burrows, Michelle Turner, Mohan Suntharalingam, James Donahue, Elizabeth M Nichols, Josephine Feliciano, Søren M Bentzen, Shahed Badiyan, Shamus R Carr, Joseph Friedberg, Charles B Simone, Martin J Edelman, Steven J Feigenberg, Pranshu Mohindra
Purpose: Guidelines for locally advanced non-small cell lung cancer (LA-NSCLC) recommend definitive chemoradiation therapy (CRT) for cN2-N3 disease, reserving surgery for patients with minimal nodal involvement at presentation. The current literature suggests that surgery after CRT for stage III NSCLC can improve freedom-from-recurrence (FFR) but has not consistently demonstrated an improvement in overall survival, perhaps partly due to the low (45-50.4 Gy) preoperative doses delivered that result in low rates of mediastinal nodal clearance...
July 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29103238/neo-adjuvant-chemo-radiation-to-60-gray-followed-by-surgery-for-locally-advanced-non-small-cell-lung-cancer-patients-evaluation-of-trimodality-strategy
#4
Sarit Appel, Jeffry Goldstein, Marina Perelman, Tatiana Rabin, Damien Urban, Amir Onn, Tiberiu R Shulimzon, Ilana Weiss, Sivan Lieberman, Edith M Marom, Nir Golan, David Simansky, Alon Ben-Nun, Yaacov Richard Lawrence, Jair Bar, Zvi Symon
BACKGROUND: Neoadjuvant chemo-radiation therapy (CRT) dosages in locally advanced non-small cell lung cancer (NSCLC) were traditionally limited to 45 Gray (Gy). OBJECTIVES: To retrospectively analyze outcomes of patients treated with 60 Gy CRT followed by surgery. METHODS: A retrospective chart review identified patients selected for CRT to 60 Gy followed by surgery between August 2012 and April 2016. Selection for surgery was based on the extent of disease, cardiopulmonary function, and response to treatment...
October 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/29066693/-the-impact-of-neutrophil-lymphocyte-ratio-on-the-prognosis-in-patients-who-underwent-esophagectomy-for-esophageal-cancer
#5
Takahiro Muroya, Naoki Wajima, Hiroshi Ogasawara, Takafumi Yachi, Takanobu Akaishi, Satoko Umetsu, Yusuke Wakasa, Tatsuya Yoshida, Kentaro Sato, Yuto Mitsuhashi, Kotaro Umemura, Takahiro Suzuki, Satoru Tsuruta, Kenichi Hakamada
BACKGROUND: Thene utrophil-lymphocyteratio (NLR)reflects a patient's systemic inflammatory response. Several studies have revealed that the NLR is associated with a poor prognosis in several types of malignant tumors such as colorectal and lung cancer. The aim of this study was to evaluate the impact of preoperative NLR on the prognosis of patients with esophageal cancer. METHODS: The NLR was calculated for 93 consecutive patients with clinical Stage II or III esophageal cancer, who underwent curative esophagectomy following neoadjuvant chemotherapy between 2011 and 2013...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29061778/anticancer-activity-of-artemisinin-and-its-derivatives
#6
REVIEW
Silvia Slezakova, Jana Ruda-Kucerova
Artemisinin is an extract from the plant Artemisia annua. With its semi-synthetic derivatives, they form a group of well-known and efficacious antimalarial drugs. Recent studies have documented the potential anticancer effect of artemisinin and its derivatives (ARTs). This review summarizes results of preclinical studies, documenting mechanisms of anticancer actions of ARTs and clinical studies focused mainly on efficacy, safety and dose-ranging of ARTs as anticancer chemotherapeutics. The main mechanisms of action of ARTs is the production of reactive oxygen species, inhibition of cell cycle in G0/G1 phase, induction of apoptosis and inhibition of angiogenesis...
November 2017: Anticancer Research
https://www.readbyqxmd.com/read/29036790/predictors-for-the-efficacy-of-endostar-combined-with-neoadjuvant-chemotherapy-for-stage-iiia-n2-nsclc
#7
Xiaoliang Zhao, Xiaohua Wen, Wei Wei, Yanjun Su, Jian You, Liqun Gong, Zhenfa Zhang, Meng Wang, Jianyu Xiao, Xiyin Wei, Changli Wang
BACKGROUND: Endostar (rh-endostatin) is a new recombinant human endostatin, which could inhibit cell proliferation, angiogenesis, and tumor growth. OBJECTIVE: To explore anti-angiogenesis short-term efficacy combined with neoadjuvant chemotherapy for stage IIIA (N2) non-small cell lung cancer (NSCLC), and identify the potential predictive factors. METHODS: We pathologically examined 26 patients diagnosed with stage IIIA (N2) NSCLC who received NP chemotherapy alone or combined with Endostar, respectively...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28977471/variations-in-gene-expression-of-lung-macromolecules-after-induction-chemotherapy-for-lung-cancer
#8
Lucio Cagini, Stefania Balloni, Vienna Ludovini, Marco Andolfi, Alberto Matricardi, Rossella Potenza, Jacopo Vannucci, Annamaria Siggillino, Francesca Romana Tofanetti, Guido Bellezza, Maria Bodo, Francesco Puma, Lorella Marinucci
OBJECTIVES: Preoperative chemotherapy may play a role in postoperative respiratory complications due to subclinical parenchymal damage. We investigated the gene expression of lung tissue components after neoadjuvant chemotherapy of alveolar-capillary membrane, extracellular matrix and membrane proteins. METHODS: The study group included 14 patients submitted to pulmonary resection for lung cancer after 3 cycles of gemcitabine-cisplatin, while the control group included 14 naive-treatment patients...
June 19, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28958107/-trimodal-therapy-for-stage-iiia-b-nsclc-involving-high-dose-neoadjuvant-chemoradiotherapy-is-surgery-a-rational-option
#9
Aris Koryllos, Corinna Ludwig, Walburga Engel-Riedel, Michaela Hammer-Helmig, Erich Stoelben
Introduction Stage III non-small cell lung cancer (NSCLC) and its possible multimodal therapy present a challenge to the responsible oncologist, chest surgeon and radiologist. The aim of the present retrospective study was to analyse and evaluate the treatment algorithm in our hospital for patients with stage III NSCLC (intention to treat). We compared an aggressive treatment regime with primary trimodal therapy (high dose radiochemotherapy and resection), independently of "multilevel" N2 or "single level" N3 status...
September 2017: Zentralblatt Für Chirurgie
https://www.readbyqxmd.com/read/28953945/incidence-and-clinical-features-of-the-incidentally-found-vascular-stump-thrombus-during-routine-follow-up-after-oncologic-lung-surgery
#10
Mi Hyoung Moon, Kyongmin Sarah Beck, Young Kyu Moon, Jae Kil Park, Sook Whan Sung
OBJECTIVES: We aimed to evaluate the incidence and clinical features of vascular stump thrombus after oncologic lung surgery. METHODS: A retrospective analysis of records from our institutional database dated between 2009 and 2016 was performed. Data regarding demographics, clinical presentation, medication use, operative findings, pathology, and radiologic findings were retrieved. RESULTS: The study cohort consisted of 648 oncologic surgeries for primary lung cancer...
2017: PloS One
https://www.readbyqxmd.com/read/28951518/immune-activation-in-early-stage-non-small-cell-lung-cancer-patients-receiving-neoadjuvant-chemotherapy-plus-ipilimumab
#11
John S Yi, Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, Jeffrey Clarke, Jeffrey Crawford, Betty C Tong, David Harpole, Thomas A D'Amico, Frances McSherry, Frank Dunphy, Shannon J McCall, Jared D Christensen, Xiaofei Wang, Kent J Weinhold
PURPOSE: To determine the immunologic effects of neoadjuvant chemotherapy plus ipilimumab in early stage non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: This is a single-arm chemotherapy plus phased ipilimumab Phase II study of 24 treatment-naïve patients with Stage IB-IIIA NSCLC. Patients received neoadjuvant therapy consisting of 3 cycles of paclitaxel with either cisplatin or carboplatin and ipilimumab included in the last 2 cycles. RESULTS: Chemotherapy alone had little effect on immune parameters in PBMCs...
September 26, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28942077/transcervical-extended-mediastinal-lymphadenectomy-experience-from-a-north-american-cancer-center
#12
Sai Yendamuri, Athar Battoo, Grace Dy, Hongbin Chen, Jorge Gomez, Anurag K Singh, Mark Hennon, Chukwumere E Nwogu, Elisabeth U Dexter, Miriam Huang, Anthony Picone, Todd L Demmy
BACKGROUND: Accurate staging of the mediastinum is a critical element of therapeutic decision making in non-small cell lung cancer. We sought to determine the utility of transcervical extended mediastinal lymphadenectomy (TEMLA) in staging non-small cell lung cancer for large central tumors and after induction therapy. METHODS: A retrospective record review was performed of all patients who underwent TEMLA at our institution from 2010 to 2015. Clinical stage as assessed by positron emission tomography integrated with computed tomography (PET-CT), stage as assessed by TEMLA, final pathologic stage, lymph node yield, and clinical characteristics of tumors were assessed along with TEMLA-related perioperative morbidity...
November 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28918673/suppression-of-tgf-%C3%AE-1-enhances-chemosensitivity-of-cisplatin-resistant-lung-cancer-cells-through-the-inhibition-of-drug-resistant-proteins
#13
Jin Wang, Yunqing Chen, Fenggang Xiang, Min Li, Hong Li, Jinghua Chi, Keyu Ren
Cisplatin-based chemotherapy is the first-line treatment for non-small cell lung cancer (NSCLC), but drug resistance occurs in most patients, leading to treatment failure. Recent studies have shown that epithelial-mesenchymal transition (EMT) is associated with drug resistance. However, the underlying mechanism is not entirely clear. In this study, first we showed significant positive correlation between the expression of ERCCl and vimentin, and significant negative correlation between the ERCCl and E-cadherin in the neoadjuvant chemotherapy group and the simple surgery group...
September 18, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28900290/alteration-of-pd-l1-expression-and-its-prognostic-impact-after-concurrent-chemoradiation-therapy-in-non-small-cell-lung-cancer-patients
#14
Daichi Fujimoto, Keiichiro Uehara, Yuki Sato, Ichiro Sakanoue, Munehiro Ito, Shunsuke Teraoka, Kazuma Nagata, Atsushi Nakagawa, Yasuhiro Kosaka, Kojiro Otsuka, Yukihiro Imai, Hiroshi Hamakawa, Yutaka Takahashi, Masaki Kokubo, Keisuke Tomii
Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD-1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CCRT on programmed cell death ligand-1 (PD-L1) expression on tumor cells is unknown. In this study, we analysed paired NSCLC specimens that had been obtained pre- and post-CCRT. PD-L1 expression on tumor cells was studied by immunohistochemistry...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28890815/the-role-of-neoadjuvant-radiotherapy-for-locally-advanced-rectal-cancer-with-resectable-synchronous-metastasis
#15
Croix C Fossum, Jasim Y Alabbad, Lindsay B Romak, Christopher L Hallemeier, Michael G Haddock, Marianne Huebner, Eric J Dozois, David W Larson
BACKGROUND: Although neoadjuvant radiotherapy is typically administered for locally-advanced rectal cancer to reduce local recurrence (LR), its role for patients who present with synchronous resectable liver and/or lung metastasis is not well defined. The aim of this study was to evaluate the role of neoadjuvant radiotherapy for patients with stage IV rectal cancer undergoing curative-intent surgery. METHODS: This study is a retrospective review of a prospectively maintained surgical registry of all consecutive adult patients who underwent curative-intent resection at Mayo Clinic in Rochester, MN, from January 1990 until December 2014 with a median follow-up time of 43 (IQR 16-67) months...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28853141/influence-of-tumor-response-and-treatment-schedule-on-the-distribution-of-tumor-recurrence-in-esophageal-cancer-patients-treated-with-neoadjuvant-chemoradiotherapy
#16
Kristien M Jipping, Jan Binne Hulshoff, Evita A van Amerongen, Tim I Bright, David I Watson, John Th M Plukker
BACKGROUND AND OBJECTIVES: The impact of different neoadjuvant chemoradiotherapy (nCRT) schedules and pathologic complete response (pCR) on the distribution of recurrence is unclear in esophageal cancer (EC). We assessed the effect of pCR and nCRT schedule in EC. METHODS: Patients with T1N+/T2-4aN0-3/M0 EC treated in different centers, with either carboplatin/paclitaxel/41.4 Gy (CROSS: n = 134) or Cisplatin/5-fluorouracil/45-50.4 Gy (Cis/5FU: n = 88) followed by surgery were included...
August 29, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28838509/initial-experience-with-lung-cancer-resection-after-treatment-with-t-cell-checkpoint-inhibitors
#17
Jamie E Chaft, Matthew D Hellmann, Moises J Velez, William D Travis, Valerie W Rusch
T-cell checkpoint inhibitors targeting the programmed death receptor-1 (PD-1) and its ligand (PD-L1) have recently been approved for the treatment of metastatic non-small cell lung cancer (NSCLC), but their safety and efficacy as neoadjuvant therapy are still undefined. Autoimmune toxicities, notably pneumonitis, are a particular concern in the perioperative setting. This series of 5 cases describes for the first time the safety and technical issues relating to pulmonary resection after checkpoint inhibitor therapy...
September 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28827262/polymorphisms-of-the-stem-cell-marker-gene-cd133-are-associated-the-clinical-outcome-in-a-cohort-of-chinese-non-small-cell-lung-cancer-patients
#18
Qing-Feng Liu, Zhi-Fei Zhang, Guang-Jie Hou, Guang-Yu Yang, Yi He
OBJECTIVES: To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in CD133 (rs2240688A>C, rs10022537T>A, rs7686732C>G, and rs3130C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients. DESIGN: Retrospective cohort study. SETTING: Department of General Surgery, in a general hospital, Henan Province, China. PARTICIPANTS: NSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion...
August 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/28819411/comprehensive-study-of-prognostic-risk-factors-of-patients-underwent-pneumonectomy
#19
Chang Gu, Rui Wang, Xufeng Pan, Qingyuan Huang, Jizhuang Luo, Jiajie Zheng, Yiyang Wang, Jianxin Shi, Haiquan Chen
Introduction: To investigate postoperative complications and the prognostic risk factors of patients underwent pneumonectomy. Methods: Four hundred and six patients underwent pneumonectomy were subjected to the study. All the clinicopathologic data including age, gender, smoking history, surgical treatment, postoperative complications, tumor staging and the follow-up information were investigated. Results: The 30-day and 90-day mortality rates were 3.2% and 6.2%, respectively. Postoperative complications developed in 149 patients (36...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28808224/off-label-use-of-crizotinib-as-a-neoadjuvant-treatment-for-a-young-patient-when-conventional-chemotherapy-gave-no-benefits-in-stage-iiia-non-small-cell-lung-cancer
#20
Delphine Dumont, Pascal Dô, Delphine Lerouge, Gaëtane Planchard, Marc Riffet, Catherine Dubos-Arvis, Serge Danhier, Radj Gervais
BACKGROUND The treatment of locally advanced non-small cell lung cancer involves a combination of chemotherapy, surgery, and radiotherapy. Each case is discussed and the best strategy is chosen individually, following international guidelines. CASE REPORT A 37-year-old man was diagnosed with locally advanced broncho-pulmonary adenocarcinoma (stage IIIA). The disease was stable after 2 cycles of cisplatin plus Navelbine used as neoadjuvant therapy. FISH analysis revealed an ALK rearrangement. The patient then received unlicensed crizotinib as second-line neoadjuvant treatment, which led to an almost complete radiological and metabolic response...
August 15, 2017: American Journal of Case Reports
keyword
keyword
52784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"